Systematic enhancement of polymerization of recombinant sickle hemoglobin mutants: implications for transgenic mouse model for sickle cell anemia.

To provide quantitative information on the sites that promote polymerization of sickle hemoglobin (HbS) after formation of the initial hydrophobic bond involving Val-6(beta) [E6V(beta)] and also to provide hemoglobins with an enhanced polymerization that could be used in a mouse model for sickle cell anemia, we have expressed recombinant double, triple, and quadruple HbS mutants with substitutions on both the alpha- and beta-chains, E6V(beta)/E121R(beta), D75Y(alpha)/E6V(beta)/E121R(beta) and D6A(alpha)/D75Y(alpha)/E6V(beta)/E121R(beta). These recombinant hemoglobins were extensively characterized by high-performance liquid chromatography analysis, sodium dodecyl sulfate-polyacrylamide gel electrophoresis, isoelectric focusing, amino acid analysis, and mass spectroscopy. They retained the functional properties of the Hb tetramer and polymerized in a linear manner at progressively lower Hb concentration as a function of the degree of substitution, suggesting that these remote sites (alphaD6A, alphaD75Y, and betaE121R) on the alpha- and beta-chains exhibit additive, enhanced polymerization properties. The quadruple mutant has a polymerization concentration close to that of the purified SAD hemoglobin from transgenic mouse red blood cells consisting of HbS, Hb Antilles, and Hb D-Punjab. Normal mouse Hb increases the polymerization concentration of each mutant. Thus, the general approach of using recombinant Hbs as described here should prove useful in elucidating the quantitative aspects of the mechanism of HbS polymerization and in identifying the contribution of individual sites to the overall process. The strategy described here demonstrates the feasibility of a systematic approach to achieve future recombinant HbS mutants that could provide a new generation of the transgenic mouse model for sickle cell anemia.

[1]  E. Rubin,et al.  A transgenic mouse model of hemoglobin S Antilles disease. , 1997, Blood.

[2]  B. Chait,et al.  A Recombinant Sickle Hemoglobin Triple Mutant with Independent Inhibitory Effects on Polymerization* , 1996, The Journal of Biological Chemistry.

[3]  B. Chait,et al.  Participation and Strength of Interaction of Lysine 95(β) in the Polymerization of Hemoglobin S as Determined by Its Site-directed Substitution by Isoleucine (*) , 1995, The Journal of Biological Chemistry.

[4]  L. R. Manning,et al.  A recombinant human hemoglobin with asparagine‐102(β) substituted by alanine has a limiting low oxygen affinity, reduced marginally by chloride , 1995, Protein science : a publication of the Protein Society.

[5]  J. Manning,et al.  Properties of a recombinant human hemoglobin double mutant: Sickle hemoglobin with Leu‐88 (β) at the primary aggregation site substituted by Ala , 1994, Protein science : a publication of the Protein Society.

[6]  B. Chait,et al.  Biochemical and functional properties of recombinant human sickle hemoglobin expressed in yeast. , 1993, The Journal of biological chemistry.

[7]  O. Schneewind,et al.  Recombinant human sickle hemoglobin expressed in yeast. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[8]  R. Nagel,et al.  High expression of human beta S- and alpha-globins in transgenic mice: hemoglobin composition and hematological consequences. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[9]  B. Chait,et al.  Weighing naked proteins: practical, high-accuracy mass measurement of peptides and proteins. , 1992, Science.

[10]  P. Romeo,et al.  Towards a transgenic mouse model of sickle cell disease: hemoglobin SAD. , 1991, The EMBO journal.

[11]  E. Rubin,et al.  Hypoxia-induced in vivo sickling of transgenic mouse red cells. , 1991, The Journal of clinical investigation.

[12]  A. Wieczorek,et al.  Synthesis of Wild Type and Mutant Human Hemoglobins in Saccharomyces cerevisiae , 1991, Bio/Technology.

[13]  W. Goebel,et al.  Rapid and efficient site-specific mutagenesis. , 1990, Protein engineering.

[14]  R. Palmiter,et al.  Human sickle hemoglobin in transgenic mice. , 1990, Science.

[15]  M. Vidal,et al.  A transgenic mouse model of sickle cell disorder , 1990, Nature.

[16]  J. Hofrichter,et al.  Sickle cell hemoglobin polymerization. , 1990, Advances in protein chemistry.

[17]  S. Watowich,et al.  Intermolecular contacts within sickle hemoglobin fibers. , 1989 .

[18]  R. Carrell,et al.  A NEW DOUBLY SUBSTITUTED SICKLING HAEMOGLOBIN: HbS‐OMAN , 1989, British journal of haematology.

[19]  E. Padlan,et al.  Refined crystal structure of deoxyhemoglobin S. I. Restrained least-squares refinement at 3.0-A resolution. , 1982, The Journal of biological chemistry.

[20]  Thomas A. Kunkel,et al.  Rapid and efficient site-specific mutagenesis without phenotypic selection. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[21]  S. Edelstein,et al.  Oblique alignment of hemoglobin S fibers in sickled cells. , 1979, Journal of molecular biology.

[22]  R. Edalji,et al.  alpha Chain mutations with opposite effects on the gelation of hemoglobin S. , 1979, The Journal of biological chemistry.

[23]  T. Imamura,et al.  Hemoglobin sawara: α 6(A4) aspartic acid → alanine , 1973 .

[24]  H. Lehmann,et al.  Hemoglobin winnipeg: Ά275 Asp → Tyr β2 , 1973 .

[25]  H. Lehmann,et al.  Hemoglobin Winnipeg: alpha2 75 Asp leads to Tyr beta2. , 1973, Clinical biochemistry.

[26]  R. Nagel,et al.  Ligand-induced conformational dependence of hemoglobin in sickling interactios. , 1971, Journal of molecular biology.

[27]  W. Dejong,et al.  Hemoglobin O arab in four negro families and its interaction with hemoglobin S and hemoglobin C. , 1970, The New England journal of medicine.

[28]  S. Charache,et al.  RATE OF SICKLING OF RED CELLS DURING DEOXYGENATION OF BLOOD FROM PERSONS WITH VARIOUS SICKLING DISORDERS. , 1964, Blood.